The cardiotoxicity of anticancer drugs represents a long-standing, important, and
widely discussed issue in medical oncology [
[1]
]. We have witnessed impressive advances in cancer management over the last decade,
with novel treatments reporting unprecedented response rates and improving clinical
outcomes in several haematological and solid tumours [
- Omland T.
- Heck S.L.
- Gulati G.
The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology
state-of-the-art review.
JACC CardioOncol. 2022 Mar 15; 4 (. PMID: 35492815; PMCID: PMC9040117): 19-37https://doi.org/10.1016/j.jaccao.2022.01.101
[2]
]. Nonetheless, if on the one hand, new therapies have showed superior efficacy; on
the other hand, these treatments have been associated with a non-negligible risk of
increased cardiac toxicities. Several types of cardiovascular toxicities have been
classically associated to anticancer therapies, including QT prolongation, coronary
heart disease, systemic hypertension, myocardial infarction, heart failure, and myocarditis.
However, different classes of anticancer drugs have shown a distinct safety profile
in terms of cardiovascular toxicities, also inducing cardiotoxicity through different
mechanisms. Based on these premises, prompt identification of treatment-related cardiotoxicity
and the role of cardioprotective therapies remain timely topics in this setting.- Livi L.
- Barletta G.
- Martella F.
- Saieva C.
- Desideri I.
- Bacci C.
- et al.
Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving
an anthracycline-based chemotherapy: a randomized clinical trial.
JAMA Oncol. 2021 Oct 1; 7 (. PMID: 34436523; PMCID: PMC8391772): 1544-1549https://doi.org/10.1001/jamaoncol.2021.3395
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review.JACC CardioOncol. 2022 Mar 15; 4 (. PMID: 35492815; PMCID: PMC9040117): 19-37https://doi.org/10.1016/j.jaccao.2022.01.101
- Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy: a randomized clinical trial.JAMA Oncol. 2021 Oct 1; 7 (. PMID: 34436523; PMCID: PMC8391772): 1544-1549https://doi.org/10.1001/jamaoncol.2021.3395
- Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: a systematic review & bayesian network meta-analysis.Eur J Cancer. 2022 May 4; 169 (Epub ahead of print. PMID: 35524992): 82-92https://doi.org/10.1016/j.ejca.2022.03.024
- Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.Res Synth Methods. 2012 Jun; 3: 98-110
- Network meta-analysis: an introduction for clinicians.Intern Emerg Med. 2017 Feb; 12 (Epub 2016 Dec 2. PMID: 27913917; PMCID: PMC5247317): 103-111https://doi.org/10.1007/s11739-016-1583-7
Article info
Publication history
Published online: July 21, 2022
Accepted:
June 9,
2022
Received:
June 5,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review & bayesian network meta-analysisEuropean Journal of CancerVol. 169
- Reply to comment on “Long-term effectiveness of empiric cardio-protection in patients receiving cardiotoxic chemotherapies: A systematic review and Bayesian network meta-analysis”European Journal of CancerVol. 174
- PreviewWe would like to thank Dr. Rizzo and Dr. Brandi for their constructive comments on our study. We concur with their statement on the importance of conducting head-to-head clinical trials that are sufficiently powered for the detection of clinically meaningful outcomes. We agree that although our analysis showed a meaningful benefit to cardioprotective therapies, it is not a substitute for such large prospective trials.
- Full-Text
- Preview
